Video

Dr. Humphrey discusses takeaways from NY GU 2022 in RCC/bladder cancer

Author(s):

Urology Times staff

In this video, Peter A. Humphrey, MD, PhD, provides an overview of some important takeaways in bladder and kidney cancer that were discussed at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Humphrey is a professor of pathology and the director of genitourinary pathology at the Yale University School of Medicine in New Haven, Connecticut.

Related Videos
Ellen Cahill, MD, answers a question during a video interview
Male doctor examining patient | Image Credit: © Rawpixel.com - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
Phase 1/2 trial launches of CAR T cell therapy for ccRCC
November 20th 2024

Phase 1/2 trial launches of CAR T cell therapy for ccRCC

Hannah Clarke
Initial results on ADI-270 are anticipated for the first half of 2025.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC
November 11th 2024

Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC

Hannah Clarke
"Together, the data point to the exciting potential for this combination regimen to be used to treat patients with muscle invasive bladder cancer," says Roger Li, MD.
female doctor talking with male patient
December 22nd 2022

Dr. Katherine Rotker on destigmatizing sexual health

Urology Times staff
"I think there's a lot of fear that can go into talking about these topics," says Katherine Rotker, MD.
ALLO-316 shows encouraging CAR activity in advanced ccRCC
November 8th 2024

ALLO-316 shows encouraging CAR activity in advanced ccRCC

Hannah Clarke
Overall, 76% of patients with a CD70 TPS of at least 50% achieved a reduction in tumor burden.
Phase 3 ENLIGHTED trial: Padeliporfin VTP shows promise in low-grade UTUC
November 7th 2024

Phase 3 ENLIGHTED trial: Padeliporfin VTP shows promise in low-grade UTUC

Hannah Clarke
At the end of the induction phase, 86% of patients had achieved a complete response.
© 2024 MJH Life Sciences

All rights reserved.